As of 2025-07-05, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -0.51. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 83.47 mil USD. FATE's TTM EBITDA according to its financial statements is -162.64 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.1x - 13.0x | 11.7x |
| Forward P/E multiples | 11.8x - 26.3x | 16.2x |
| Fair Price | (16.35) - (18.00) | (19.44) |
| Upside | -1559.8% - -1706.8% | -1835.3% |
| Date | EV/EBITDA |
| 2025-07-03 | -0.51 |
| 2025-07-02 | -0.51 |
| 2025-07-01 | -0.53 |
| 2025-06-30 | -0.51 |
| 2025-06-27 | -0.46 |
| 2025-06-26 | -0.50 |
| 2025-06-25 | -0.54 |
| 2025-06-24 | -0.55 |
| 2025-06-23 | -0.53 |
| 2025-06-20 | -0.56 |
| 2025-06-18 | -0.58 |
| 2025-06-17 | -0.57 |
| 2025-06-16 | -0.60 |
| 2025-06-13 | -0.62 |
| 2025-06-12 | -0.71 |
| 2025-06-11 | -0.82 |
| 2025-06-10 | -0.90 |
| 2025-06-09 | -0.80 |
| 2025-06-06 | -0.85 |
| 2025-06-05 | -0.67 |
| 2025-06-04 | -0.72 |
| 2025-06-03 | -0.68 |
| 2025-06-02 | -0.64 |
| 2025-05-30 | -0.58 |
| 2025-05-29 | -0.65 |
| 2025-05-28 | -0.62 |
| 2025-05-27 | -0.58 |
| 2025-05-23 | -0.54 |
| 2025-05-22 | -0.57 |
| 2025-05-21 | -0.55 |
| 2025-05-20 | -0.60 |
| 2025-05-19 | -0.58 |
| 2025-05-16 | -0.48 |
| 2025-05-15 | -0.44 |
| 2025-05-14 | -0.40 |
| 2025-05-13 | -0.43 |
| 2025-05-12 | -0.48 |
| 2025-05-09 | -0.46 |
| 2025-05-08 | -0.45 |
| 2025-05-07 | -0.43 |
| 2025-05-06 | -0.40 |
| 2025-05-05 | -0.55 |
| 2025-05-02 | -0.65 |
| 2025-05-01 | -0.60 |
| 2025-04-30 | -0.63 |
| 2025-04-29 | -0.55 |
| 2025-04-28 | -0.60 |
| 2025-04-25 | -0.63 |
| 2025-04-24 | -0.68 |
| 2025-04-23 | -0.66 |